Akademik Veri Yönetim Sistemi
5th NOVEL FLUIDIC TECHNOLOGIES WORKSHOP WITH AN EMPHASIS ON TISSUE ENGINEERING, İzmir, Türkiye, 4 - 05 Mayıs 2023, ss.32
Ophthalmic diseases originating from trauma, inherited genetic background or as result of other systemic diseases affects a large portion of the human population. Advances in cell-based therapies promise to improve the vision and patient comfort. Today novel regenerative medicine approaches in ophthalmology have been significantly influenced by induced pluripotent stem cells (iPSCs) and their potential in ocular disease modeling and treatment of ocular diseases. iPSCs have been successfully demonstrated to form organoids, organ mimicries recapitulating cellular phenotypes and functions of organs/tissues in vitro. Anterior and posterior eye compartments have been addressed utilizing organoid technologies to elaborate the development of human eye and generate disease models. Cornea, retina, and lacrimal gland organoids have been generated from iPSCs and efforts to use them in associated diseases attracts tremendous interest.
Organ-on-a-chip (OoC) platforms mimicking native microphysiological environments have been established that allow cell differentiation and tissue growth rather than using research animals to improve the in vitro models. Such tools facilitate investigation of cellular mechanotransduction, tissue morphogenesis and advanced control of other physiological factors affecting in vitro performance of organoids. As growing interest of pharma industry on bioengineered OoCs, organoid models in eye research become more attractive.
ACKNOWLEDGEMENT:
The author has been supported by TÜBİTAK projects 117S264 and 121C313, TÜBA-GEBİP and BAGEP awards.